전체 프로그램

ADC 890 · Antibody 4071 · CGT 2714 · 다음 갱신 D-4 · 마지막 9월 2일

PopularRecently updatedCuratedMost trialsNeeds refreshORRLatestPhase 3FDA approved3 programs
CGTCurated CoreFDAFerring PharmaceuticalsApproved

nadofaragene firadenovec (Adstiladrin, rAd-IFNα/Syn3, nadofaragene firadenovec-vncg)

High-risk BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) · IFNα2b (adenoviral)

#IFN2badenoviral#CGT#Approved#FDA-approved#BioJungboMoa-pick+5
Trials 10Status Approved
ADCLimited DatastaleRemeGenPhase 2

disitamab vedotin (Disitamab Vedotin, RC48, Disitamab Vedotin combined with Radiotherapy)

HER2-expressing High-risk or Very High-risk NMIBC Without Visible Foci of Disease After TURBT · HER2

#HER2#ADC#Phase2#antibody-drug-conjugate#HER2-expressingHigh-riskorVeryHi+1
Trials 1Status Recruiting
CGTLimited DatastaleDing-Wei YePhase 2

VG161 via Intravesical Instillation (VG161 via Intravesical Instillation)

NMIBC · NMIBC

#NMIBC#CGT#Phase2#cell-gene-therapy#CAR-T+2
Trials 1Status Active